Pfizer Better Able To De-Risk First-In-Class Compounds, R&D Head Says
Executive Summary
Pfizer has become more effective at controlling the development risk of investigational compounds with novel mechanisms of action, Global Research & Development President John LaMattina asserted Nov. 30
You may also be interested in...
Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
As Andrew Witty takes the helm at GlaxoSmithKline, he has set his sights on tackling one of the industry's biggest challenges: reducing attrition in the late-stage pipeline
Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
As Andrew Witty takes the helm at GlaxoSmithKline, he has set his sights on tackling one of the industry's biggest challenges: reducing attrition in the late-stage pipeline
Pfizer Looks To Combination Regimens To Maximize Oncology Pipeline Value
Pfizer is seeking to maximize the value of its oncology pipeline by developing combination regimens, Senior VP-Worldwide Development Declan Doogan said Nov. 30